title: Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer.
abstract: Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VP16) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16 BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7%) complete responses (CR) and 9 (33%) partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of 21 (33%) patients previously treated with VP16 responded to DDP plus VP16 (D-V). These results confirm D-V regimen as active in SCLC patients even when heavily pretreated. Our 33% response in patients who had VP16 in their induction treatment regimen provides further evidence of an important potentiating effect of DDP, as reported in animal system.
authors.affiliation: Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Figoli
authors.forename: A
authors.initials: A
authors.lastname: Veronesi
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: L
authors.initials: L
authors.lastname: Canobbio
authors.forename: G
authors.initials: G
authors.lastname: Bruschi
authors.forename: F
authors.initials: F
authors.lastname: Mazza
authors.forename: V
authors.initials: V
authors.lastname: Zagonel
authors.forename: G
authors.initials: G
authors.lastname: Lo Re
authors.forename: R
authors.initials: R
authors.lastname: Rosso
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D005047:Etoposide; D002945:Cisplatin